quinuclidines has been researched along with Motion Sickness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boucher, JF; Clemence, RG; Conder, GA; Sedlacek, HS | 1 |
| Benchaoui, HA; Clemence, RG; De La Puente-Redondo, VA; Rowan, TG; Siedek, EM; Tilt, N | 1 |
| Bunger, A; Cox, SR; Hickman, MA; Lin, J; Mahabir, S; McCall, RB; Miskell, C | 1 |
1 trial(s) available for quinuclidines and Motion Sickness
| Article | Year |
|---|---|
Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.
Topics: Animals; Antiemetics; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Motion Sickness; Quinuclidines; Treatment Outcome; Vomiting | 2007 |
2 other study(ies) available for quinuclidines and Motion Sickness
| Article | Year |
|---|---|
Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
Topics: Animals; Cross-Over Studies; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Male; Motion Sickness; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Topics: Animals; Cats; Female; Male; Metabolic Clearance Rate; Motion Sickness; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |